STAg inhibits fusion of cells expressing R5 but not X4 HIV-1 envelopes
. | . | % Fusion inhibition*R5 . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Target . | Inhibitor (μg/mL) . | JR-FL . | ADA . | Ba-L . | X4 IIIB . | ||
| PM1† | RANTES (1) | 100 | 99 | 100 | 0 | ||
| SDF1 (1) | 0 | 0 | 0 | 99 | |||
| STAg (10) | 58 | 60 | 62 | 0 | |||
| (3.3) | 31 | 44 | 50 | 0 | |||
| (1.0) | 12 | 15 | 23 | 0 | |||
| ID50 | 7.0 μg/mL | 5.3 μg/mL | 4.4 μg/mL | — | |||
. | . | % Fusion inhibition*R5 . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Target . | Inhibitor (μg/mL) . | JR-FL . | ADA . | Ba-L . | X4 IIIB . | ||
| PM1† | RANTES (1) | 100 | 99 | 100 | 0 | ||
| SDF1 (1) | 0 | 0 | 0 | 99 | |||
| STAg (10) | 58 | 60 | 62 | 0 | |||
| (3.3) | 31 | 44 | 50 | 0 | |||
| (1.0) | 12 | 15 | 23 | 0 | |||
| ID50 | 7.0 μg/mL | 5.3 μg/mL | 4.4 μg/mL | — | |||
ID50 indicates 50% inhibitory dose; —, no inhibitory activity.
HIV-1 envelope-expressing effector cells were generated by infecting 12E1 cells overnight (10 pfu/cell) with the following recombinant vaccinia viruses expressing R5 envelopes: vCB28 (JR-FL), vCB39 (ADA), and vCB43 (Ba-L). TF228 cell line, expressing IIIB (BH10) Env, was used to measure X4-envelope fusion. Number of syncytia in control cultures (no inhibitor present) after 4 hours coculture of effector cells with PM1 target cells: JR-FL, 344 ± 28; ADA, 414 ± 44; Ba-L, 400 ± 74; and IIIB, 335 ± 15. All groups were set up in triplicates.
PM1 T cells express CD4, CXCR4, and CCR5.